Mechanism of new antipsychotic medications: occupancy is not just antagonism
- PMID: 14557141
- DOI: 10.1001/archpsyc.60.10.974
Mechanism of new antipsychotic medications: occupancy is not just antagonism
Abstract
Antagonism of D2-like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80% (striatal) D2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D2-like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is aripiprazole's weak partial agonism at D2-like dopamine receptors. This particular pharmacologic feature characterizes a new class of atypical antipsychotics that does not match the original concept of a therapeutic occupancy window for antagonist antipsychotics. When not involving pure antagonists, it implies a need to adjust the expected receptor occupancy (measured using positron emission tomography) for the therapeutic window.
Similar articles
-
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.Am J Psychiatry. 2007 Sep;164(9):1411-7. doi: 10.1176/appi.ajp.2007.06091479. Am J Psychiatry. 2007. PMID: 17728427 Clinical Trial.
-
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.Neuropsychopharmacology. 2002 Aug;27(2):248-59. doi: 10.1016/S0893-133X(02)00304-4. Neuropsychopharmacology. 2002. PMID: 12093598
-
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Neuropsychopharmacology. 2008 Dec;33(13):3111-25. doi: 10.1038/npp.2008.33. Epub 2008 Apr 16. Neuropsychopharmacology. 2008. PMID: 18418366
-
[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012. PMID: 22568121 Review. Japanese.
-
Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.Drugs Today (Barc). 2003 Feb;39(2):145-51. doi: 10.1358/dot.2003.39.2.799421. Drugs Today (Barc). 2003. PMID: 12698209 Review.
Cited by
-
Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.Psychopharmacology (Berl). 2013 Jan;225(2):329-39. doi: 10.1007/s00213-012-2815-9. Epub 2012 Aug 7. Psychopharmacology (Berl). 2013. PMID: 22868411
-
Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.Pharmacol Rev. 2010 Dec;62(4):701-25. doi: 10.1124/pr.110.002667. Pharmacol Rev. 2010. PMID: 21079041 Free PMC article. Review.
-
Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.CNS Drugs. 2006;20(5):389-409. doi: 10.2165/00023210-200620050-00004. CNS Drugs. 2006. PMID: 16696579 Review.
-
Treatment of tardive dyskinesia with aripiprazole.Neurotox Res. 2010 May;17(4):432-4. doi: 10.1007/s12640-009-9123-0. Epub 2009 Oct 14. Neurotox Res. 2010. PMID: 19826893
-
Dopamine D2/3 Receptor Availabilities in Striatal and Extrastriatal Regions of the Adult Human Brain: Comparison of Four Methods of Analysis.Neurochem Res. 2023 May;48(5):1517-1530. doi: 10.1007/s11064-022-03825-4. Epub 2022 Dec 16. Neurochem Res. 2023. PMID: 36525123
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
